β-Blocker dosing in community-based treatment of heart failure

American Heart Journal

Volumn 153, Issue 6, 2007, Pages 1029-1036

  Fowler, Michael B ^a   Lottes, Sandra R ^b   Nelson, Jeanenne J ^b   Lukas, Mary Ann ^b   Gilbert, Edward M ^c   Greenberg, Barry ^d   Massie, Barry M ^e   Abraham, William T ^f   Franciosa, Joseph A ^a,g  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL;

AGED; ARTICLE; CARDIOLOGIST; COMMUNITY; DEATH; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; GROUP THERAPY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; RISK FACTOR; STATISTICAL SIGNIFICANCE; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; AGED; CARBAZOLES; COMMUNITY NETWORKS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PRESCRIPTIONS, DRUG; PROPANOLAMINES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; UNITED STATES;

EID: 34249326909     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.03.010     Document Type: Article

References (25)

1. Philbin E.F., Rocco T.A., Lindenmuth N.W., et al. Clinical outcomes in heart failure: report from a community hospital-based registry. Am J Med 107 (1999) 549-555
2. Chin M.H., Friedmann P.D., Cassel C.K., et al. Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure. J Gen Intern Med 12 (1997) 523-530
3. Edep M.E., Shah N.B., Tateo I.M., et al. Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines. J Am Coll Cardiol 30 (1997) 518-526
4. Franciosa J.A., Massie B.M., Lukas M.A., et al., for the COHERE Participant Physicians. Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry. Am Heart J 148 (2004) 718-726
5. Franciosa J.A. The potential role of community-based registries to complement the limited applicability of clinical trial results to the community setting: heart failure as an example. Am J Manag Care 10 (2004) 487-492
6. Stafford R.S., and Radley D.C. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol 41 (2003) 56-61
7. Gupta R., Tang W.H., and Young J.B. Patterns of beta-blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic. Am Heart J 147 (2004) 79-83
8. Maggioni A.P., Sinagra G., Opasich C., et al. Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. Heart 89 (2003) 299-305
9. Mehta P.A., McDonagh S., Poole-Wilson P.A., et al. Heart failure in a district general hospital: are target doses of beta-blockers realistic?. Q J Med 97 (2004) 133-139
10. Young D., and McGuire M. Few CHF patients achieve target dosages of beta blockers, risking hospitalizations and death. Formulary 37 (2002) 321
11. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334 (1996) 1349-1355
12. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999) 9-13
13. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
14. Brophy J.M., Joseph L., and Rouleau J.L. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 134 (2001) 550-560
15. Bristow M.R., Gilbert E.M., Abraham W.T., et al., for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94 (1996) 2807-2816
16. Krum H., Roecker E.B., Mohacsi P., et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 289 (2003) 712-718
17. Wikstrand J., Hjalmarson A., Waagstein F., et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 40 (2002) 491-498
18. Simon T., Mary-Krause M., Funck-Brentano C., et al. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). Eur Heart. J 24 (2003) 552-559
19. Franciosa J.A., Abraham W.T., Fowler M., et al., for the COHERE Participant Physicians. Rationale, design, and methods for a Coreg (Carvedilol) Heart Failure Registry (COHERE). J Cardiac Fail 6 (2000) 264-271
20. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 362 (2003) 7-13
21. Rutten F.H., Grobbee D.E., and Hoes A.W. Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice. Eur J Heart Fail 5 (2003) 337-344
22. Philbin E.F., Andreaou C., Rocco T.A., et al. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol 77 (1996) 832-838
23. Fowler M.B., Vera-Llonch M., Oster G., et al. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. J Am Coll Cardiol 37 (2001) 1692-1699
24. Packer M., Poole-Wilson P.A., Armstrong P.W., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and morality in chronic heart failure. ATLAS Study Group. Circulation 100 (1999) 2312-2318
25. Massie BM, Nelson JJ, Lukas MA, et al, and the COHERE Participant Physicians. Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in heart failure patients in clinical practice. Am J Cardiol [in press].